Ultragenyx Pharmaceutical Inc.

+1.47 (+1.88%)
: $81.00 +1.31 (+1.64%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)5.41B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$81.54 Million
Adjusted EPS-$1.39
See more estimates
10-Day MA$79.83
50-Day MA$89.33
200-Day MA$106.37
See more pivots

Ultragenyx Pharmaceutical Inc. Stock, NASDAQ:RARE

60 Leveroni Court, Novato, California 94949
United States of America
Phone: +1.415.483.8800
Number of Employees: 893


Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. Mepsevii is an intravenous, which is used for the treatment of Mucopolysaccharidosis VII. Crysvita is an antibody administered via subcutaneous injection used for the treatment of XLH. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.